Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence

The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with the tumor-promoting intracellular signa...

Descripción completa

Detalles Bibliográficos
Autor principal: Rothschild, Sacha I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217508/
https://www.ncbi.nlm.nih.gov/pubmed/28210142
http://dx.doi.org/10.2147/LCTT.S49490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217508/
https://www.ncbi.nlm.nih.gov/pubmed/28210142
http://dx.doi.org/10.2147/LCTT.S49490

Ejemplares similares